Our results validate the protective efficacy of Edaravone dexborneol in OGD/R-induced microglia and MCAO rats. This effect may be attributed to its ability to mitigate neuroinflammation by modulating microglial M1/M2 polarization in vitro and inhibiting the CXCL13/CXCR5 axis and its associated NF-κB signaling pathway in vivo.